Avidity biosciences reports fourth quarter and year-end 2020 financial results and recent highlights

La jolla, calif., march 15, 2021 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called antibody oligonucleotide conjugates (aocs™), today reported financial results for the fourth quarter and year ended december 31, 2020 and highlighted recent corporate progress.
RNA Ratings Summary
RNA Quant Ranking